Ipilimumab and nivolumab followed by chemoradiotherapy as bladder-sparing treatment in muscle-invasive bladder cancer: a phase 2 trial
Jan-Jaap J. Mellema, Chantal F. Stockem, Cameron Herberts, Samantha K. Cheung, Daniël J. Vis, Bas W. G. van Rhijn, Laura S. Mertens, Thierry N. Boellaard, Maurits L. van Montfoort, Sara Balduzzi, Jeantine M. de Feijter, Johannes C. Mijn, Shruti Sharma, Adam C. El Naggar, Joost L. Boormans, Martine Franckena, Richard P. Meijer, Juus L Noteboom, Eva E. Schaake, Debbie G. J. Robbrecht, Britt BM Suelmann, Michiel S. van der Heijden
Topics & Concepts
NivolumabMedicineIpilimumabInternal medicineClinical endpointOncologyChemoradiotherapyAdverse effectBladder cancerImmunotherapyPerioperativeCystectomyPhases of clinical researchSurgeryStage (stratigraphy)Confidence intervalUrologyClinical trialCancerRandomized controlled trialNeoadjuvant therapyImmune checkpointUrinary systemInduction therapyProgression-free survivalDurvalumabBladder and Urothelial Cancer TreatmentsUrinary and Genital Oncology StudiesCancer Immunotherapy and Biomarkers